title: The microvasculature in myeloproliferative disease. A study using retinal fluorescein angiography.
abstract: Microvascular occlusion is known to be a feature of myeloproliferative diseases. Acute manifestations are well documented in individuals causing a variety of symptoms. However, it is not known whether ongoing microvascular changes are present in asymptomatic individuals. We investigated this further by using retinal intravenous fluorescein angiography to image the microvasculature in patients with myeloproliferative disease. In our group of patients fluorescein angiography did not show any ongoing microvascular damage. There appears to be no intrinsic retinal vasculopathy in patients with myeloproliferative disease, suggesting that acute symptomatic events are caused by microemboli in an otherwise normal vascular tree.
authors.affiliation: Department of Ophthalmology, Royal Hallamshire Hospital, Sheffield, UK.
authors.forename: R B
authors.initials: RB
authors.lastname: Dapling
authors.forename: J A
authors.initials: JA
authors.lastname: Snowden
authors.forename: J
authors.initials: J
authors.lastname: West
authors.forename: J F
authors.initials: JF
authors.lastname: Talbot
authors.forename: M E
authors.initials: ME
authors.lastname: Nelson
authors.forename: M
authors.initials: M
authors.lastname: Greaves
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000485:Allergens / Q000502:physiology; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001157:Arterial Occlusive Diseases / Q000097:blood* / Q000209:etiology; D001241:Aspirin / Q000627:therapeutic use; D002066:Busulfan / Q000627:therapeutic use; D005124:Eye Abnormalities; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008833:Microcirculation / Q000000981:diagnostic imaging; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000097:blood* / Q000150:complications; D017202:Myocardial Ischemia; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D010976:Platelet Count / Q000187:drug effects; D011086:Polycythemia / Q000097:blood / Q000503:physiopathology; D011877:Radionuclide Imaging; D012166:Retinal Hemorrhage / Q000139:chemically induced; D012171:Retinal Vessels / Q000000981:diagnostic imaging*; D013922:Thrombocytosis / Q000097:blood / Q000150:complications; D014792:Visual Acuity
chemical_list: D000485:Allergens; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D010975:Platelet Aggregation Inhibitors; D002066:Busulfan; D001241:Aspirin; D006918:Hydroxyurea